Search

everythinglearnresearchcommunity

for

Search:↓

A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.

Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Tofacitinib might be used to treat hair loss.

Tofacitinib taken by mouth helps treat hair loss in children.

Skin side effects from melanoma immunotherapy are common and may indicate better survival.

Rituximab leads to longer remission and fewer side effects than cyclophosphamide.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

Tocilizumab might be an effective treatment for COVID-19.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

IL-12/23 inhibitors are more effective and have fewer common side effects than anti-TNF alpha for treating psoriasis.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Canakinumab's effect on COVID-19 outcomes is unclear.

Secukinumab reduces immune activity in hidradenitis suppurativa skin.

Anti-DFS70 antibodies can help identify nonsystemic autoimmune conditions in SLE patients.

Anifrolumab improves quality of life and reduces steroid use in SLE patients.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.